Critical appraisal:Standfield L, Weston AR, Barraclough H, Van Kooten M, Pavlakis N 2011
From Cancer Guidelines Wiki
Critical Appraisal
Article being appraised
Standfield L, Weston AR, Barraclough H, Van Kooten M, Pavlakis N. Histology as a treatment effect modifier in advanced non-small cell lung cancer: a systematic review of the evidence. Respirology 2011 Nov;16(8):1210-20 Available from: http://www.ncbi.nlm.nih.gov/pubmed/21801275.
Applicable clinical question
Key Facts
Study Design
systematic review — RCTs and meta-analyses of RCTs Studies spilt into varying categories N below relates to : Category E studies: treatment effect modification by histology (with formal treatment-by-histology test
Number of Patients:
5851
Includes an economic evaluation
no
Evidence ratings
Level of evidence
I
Risk of bias
| High risk of bias | Comments: Please replace this text and include any additional comments in regards to your quality rating |
Size of effect
| 1 | Reason for decision: No pooling of study data undertaken because of heterogeneity of designs and study arms. There was consistency only amongst the 3 pemetrexed studies. |
Relevance of evidence
| 1 | Additional comments: treatment by histology interaction for ket clinical endpoints |
Result of appraisal
Included
Completed by
This appraisal has been completed.
- Article
- Standfield L, Weston AR, Barraclough H, Van Kooten M, Pavlakis N. Histology as a treatment effect modifier in advanced non-small cell lung cancer: a systematic review of the evidence. Respirology 2011 Nov;16(8):1210-20 Available from: http://www.ncbi.nlm.nih.gov/pubmed/21801275.
- Assigned to
- User:Nick.pavlakis
- Topic area
- Guidelines:Guidelines:Lung cancer/Treatment/Non-small-cell stage IV inoperable
- Clinical question
Section below only relevant for Cancer Council Project Officer